The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
UF Health Hospitals Rely on Green Globes to Realize Their Full Potential
How Healthcare Facilities Can Be Truly Disaster-Resilient
TriasMD Breaks Ground on DISC Surgery Center for San Fernando Valley
Bigfork Valley Hospital Falls Victim to Data Breach
AI-Driven Facilities: Strategic Planning and Cost Management